Is Jasper Therapeutics, Inc. (JSPR) a Buy, Sell, or Hold?
NASDAQ : JSPR
Jasper Therapeutics, Inc. — News
$0.9513 USD
$0.15 (19.0%)
- Volume
- 1.2M
- Average Volume
- 1.14M
- Market Capitalization
- $15.46M
- P/E Ratio
- -0.28
- Dividend Yield
- 0.00%
- Price Target
- $3.00
- Year High
- $3.14
- Year Low
- $0.32
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.26
| Source | Headline |
|---|---|
|
Jasper Closes Kira Deal, Extends Cash Runway
Jasper Therapeutics Inc. (NASDAQ:JSPR) on Thursday said it completed its all-stock acquisition of Kira Pharmaceuticals, bringing the two biotechnology companies together to advance a unified pipeline of therapies targeting immune-mediated and autoantibody-driven diseases. benzinga.com - 2026-07-17 13:08:07 |
|
Jasper Therapeutics Announces Merger with Kira Pharmaceuticals
Combined company positioned to advance portfolio of biologic agents designed to improve outcomes in patients with numerous immunologically-driven disorders globenewswire.com - 2026-07-16 17:15:00 |
|
Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now
Jasper Therapeutics (JSPR) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. zacks.com - 2026-06-03 10:56:17 |
|
Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that, following an evaluation of current market conditions, its Board of Directors has decided to initiate a comprehensive review of strategic alternatives aimed at maximizing shareholder value. globenewswire.com - 2026-06-01 08:00:00 |
|
Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
REDWOOD CITY, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended March 31, 2026 and provided a corporate update. globenewswire.com - 2026-05-14 16:05:00 |
